Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
基本信息
- 批准号:10390354
- 负责人:
- 金额:$ 72.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-09 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdultAdverse drug eventAdverse effectsAdverse eventAffectAfrican AmericanAgeAgingAnalytical ChemistryAnti-Retroviral AgentsAutomobile DrivingBiological AgingBiological MarkersBiological Specimen BanksBody WeightCD4 Positive T LymphocytesCell CountCharacteristicsClinicalClinical PharmacologyClinical TrialsClinical effectivenessCohort StudiesComplexDataDrug ApprovalDrug EvaluationDrug ExposureDrug KineticsDrug ModelingsElderlyEnrollmentEpidemicExposure toFemaleGeneticGoalsHIVHIV-1HispanicHormonalHourImmunologicsIncidenceInsulin ResistanceIntegraseIntegrase InhibitorsInvestigationKnowledgeLaboratoriesLatina PopulationMeasuresMetabolicMethodsModelingMorbidity - disease rateOutcomeParticipantPatientsPeripheral Blood Mononuclear CellPersonsPharmaceutical PreparationsPharmacogeneticsPharmacogenomicsPhasePhase III Clinical TrialsPhenotypePlasmaPlasma CellsPopulationPopulation HeterogeneityRNARecoveryRegimenResearchRiskRisk EstimateRisk FactorsSamplingSiteSpan 20SpecimenTenofovirTestingToxic effectValidationViralVisitWaist-Hip RatioWeight GainWomanWorkadverse event riskage effectage relatedantiretroviral therapybasecohortdiagnostic tooldrug clearanceethnic diversityevidence baseevidence based guidelinesexperiencefrailtyhigh riskimprovedindividual variationinhibitorinterestmenmortalityolder patientpatient subsetspharmacodynamic modelpharmacokinetic modelpharmacokinetics and pharmacodynamicsprecision medicineprospectiveresponsesexsocioeconomicstooltreatment responsewomen of color
项目摘要
ABSTRACT
The long-term objective of the proposed work is to provide evidenced-based recommendations for minimizing
metabolic adverse events, particularly weight gain, in a diverse population of people living with HIV (PLWH) by
identifying and quantifying variability in drug exposure that may increase risk in patient subgroups. We will
consider a broad array of modifying factors of drug exposure, including demographic characteristics, prior
laboratory values, body anthropometrics, frailty phenotype, and pharmacogenomics. Our focus is on the
integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG) and bictegravir (BIC), as well as tenofovir
alafenamide (TAF). The MWCCS includes diverse PLWH underrepresented in Phase III clinical trials and thus,
in the sponsor-developed population pharmacokinetic models of the drug. In AIM 1, we will enroll diverse PLWH
from four MWCCS sites to collect pharmacokinetic data and further refine the knowledge of factors that influence
DTG, BIC, and TAF pharmacokinetics. Drug concentrations will be measured in blood plasma and peripheral
blood mononuclear cells (TAF only) in the UNC Center for AIDS Research Clinical Pharmacology and Analytical
Chemistry Laboratory (CFAR CPAC). Nonlinear mixed effects models will be used to develop a comprehensive
PK model for each drug of interest. Using these models, then, in AIM 2, we will retrospectively measure drug
concentrations in repository specimens (using the same methods and laboratory as AIM 1, and predict drug
clearance in men and women from initiation of DTG, BIC, and/or TAF. These drug clearances, predicted for
multiple visits per participant, will then be analyzed as the predictors of body weight gain, increased waist to hip
ratio, and increased insulin resistance (as measured by HOMA-IR) over the course of treatment on the drug of
interest, with multiple measures of drug exposure. The hypothesis is that those PLWH with higher drug exposure
(via slower drug clearance) will be more likely to experience the metabolic adverse events of these drugs. Upon
completion, we expect to have the underpinnings of a model-based risk estimator developed for further
prospective validation.
摘要
拟议工作的长期目标是提供基于证据的建议,以尽量减少
代谢不良事件,特别是体重增加,在不同人群的艾滋病毒感染者(PLWH),
识别和量化可能增加患者亚组风险的药物暴露变异性。我们将
考虑药物暴露的各种修改因素,包括人口统计学特征,
实验室值、人体测量学、虚弱表型和药物基因组学。我们的重点是
整合酶链转移抑制剂(INSTI)度鲁特韦(DTG)和比替拉韦(BIC),以及替诺福韦
艾拉酚胺(TAF)。MWCCS包括在III期临床试验中代表性不足的各种PLWH,因此,
研究人员开发的药物的群体药代动力学模型。在AIM 1中,我们将招募不同的PLWH
从四个MWCCS中心收集药代动力学数据,并进一步完善影响
DTG、BIC和TAF药代动力学。将测量血浆和外周血中的药物浓度
血液单核细胞(仅TAF),在美国艾滋病研究中心临床药理学和分析
化学实验室(CFAR CPAC)。非线性混合效应模型将用于制定一个全面的
每种目标药物的PK模型。使用这些模型,然后,在AIM 2中,我们将回顾性地测量药物
储存库标本中的浓度(使用与AIM 1相同的方法和实验室,并预测药物
男性和女性从DTG、BIC和/或TAF开始的清除率。这些药物清除率,预计
每名参与者多次就诊,然后将其作为体重增加、腰臀比增加的预测因素进行分析。
胰岛素抵抗增加(通过HOMA-IR测量)
兴趣,与药物暴露的多种措施。假设是那些接触药物较多的艾滋病毒携带者
(via药物清除较慢)将更有可能经历这些药物的代谢不良事件。后
完成后,我们希望有一个基于模型的风险估计的基础,进一步发展
前瞻性验证
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julie Brumer Dumond其他文献
Julie Brumer Dumond的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julie Brumer Dumond', 18)}}的其他基金
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:
10600858 - 财政年份:2021
- 资助金额:
$ 72.48万 - 项目类别:
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:
10161378 - 财政年份:2021
- 资助金额:
$ 72.48万 - 项目类别:
Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort
WIHS 队列中衰老和炎症对细胞内核苷逆转录酶抑制剂药理学的影响
- 批准号:
9791318 - 财政年份:2018
- 资助金额:
$ 72.48万 - 项目类别:
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity
基于生理学的药代动力学模型指导肥胖儿童的药物剂量
- 批准号:
10456301 - 财政年份:2018
- 资助金额:
$ 72.48万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8231979 - 财政年份:2011
- 资助金额:
$ 72.48万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8814163 - 财政年份:2011
- 资助金额:
$ 72.48万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8140850 - 财政年份:2011
- 资助金额:
$ 72.48万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8607112 - 财政年份:2011
- 资助金额:
$ 72.48万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8429489 - 财政年份:2011
- 资助金额:
$ 72.48万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 72.48万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 72.48万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 72.48万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 72.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 72.48万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 72.48万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 72.48万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 72.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 72.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 72.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)